Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction

Cancer

Volumn 103, Issue 10, 2005, Pages 1996-2005

  Melnikow, Joy ^a   Paterniti, Debora ^b   Azari, Rahman ^b   Kuenneth, Christina ^b   Birch, Stephen ^c   Kuppermann, Miriam ^d   Nuovo, James ^a   Keyzer, Janet ^b   Henderson, Stuart ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Decision making; Prevention and control; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CATARACT; DECISION MAKING; DRUG COST; DYSPAREUNIA; ENDOMETRIUM CARCINOMA; FEMALE; FRACTURE; HUMAN; INCOME; INTERVIEW; LANGUAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MONEY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PERCEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNIVERSITY;

ADULT; AGED; ANTICARCINOGENIC AGENTS; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CATARACT; CHEMOPREVENTION; CROSS-SECTIONAL STUDIES; DECISION MAKING; DYSPAREUNIA; FEMALE; FRACTURES, BONE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INCOME; MIDDLE AGED; PATIENT EDUCATION; PATIENT SATISFACTION; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN;

EID: 18044394762     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20981     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 998;90:1371-1388.
3. Veronesi U, Maisonneuvre P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93-97.
4. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98-101.
5. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
6. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
7. Wooltorton E. Tamoxifen for breast cancer prevention: safety warning. CMAJ. 2002;167:378-379.
8. Levine M, Moutquin JM, Walton R, et al. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 2001;164:1681-1690.
9. U.S. Preventive Services Taxk Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002;137:56-58.
10. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526-532.
11. Green J, Britten N. Qualitative research and evidence based medicine. BMJ. 1998;316:1230-1232.
12. Breast Cancer Risk Assessment Program. Available from URL: http://bcra.nci.nih.gov/brc/ [accessed April 2005].
13. Kuppermann M, Nease RF, Gates E, et al. How do women of diverse backgrounds value prenatal testing? Prenat Diagn. 2004;24:424-429.
14. Burnham KP, Anderson DR. Model selection and multi-model inference. A practical information-theoretic approach, 2nd ed (2002), 3rd printing. New York: Springer, 2004.
15. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829-1846.
16. Tobias JS. Recent advances in endocrine therapy for post-menopausal women with early breast cancer: implications for treatment and prevention. Ann Oncol. 2004;15:1738-1747.
17. Bastian LA, Lipkus IM, Juchibhatla MN, et al. Women's interest in chemoprevention for breast cancer. Arch Intern Med. 2001;161:1639-1644.
18. Port ER, Montgomery LL, Heerdt AS, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580-585.
19. Fuchs V. Time preference and health: an exploratory study. In: Fuchs V, editor. Economic aspects of health. Chicago: University of Chicago Press, 1982:93-120.
20. Mulley AG, Sepucha K. Making good decisions about breast cancer chemoprevention. Ann Intern Med. 2002;137:52-54.
21. Rockhill B, Colditz G, Kaye J. Re: tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst. 2000;92:659-660.
22. Will BP, Nobrega KM, Berthelot J-M, et al. First do no harm: extending the debate on the provision of preventive tamoxifen. Br J Cancer. 2001;85:1280-1288.